₩304,500+33500.00 (+12.36%)
LG Chem, Ltd., together with its subsidiaries, operates as a chemical company in Korea, China, Asia/Oceania, the United States, Europe, and internationally.
LG Chem, Ltd. in the Basic Materials sector is trading at $304,000 with a market capitalization of $24.8T. Wall Street consensus targets $446,840 (25 analysts), implying a +47.0% move over the next 12 months. The stock is currently 31% below its 52-week high of $437,500, remaining 10.8% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (KRW) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | ₩12.58T↑ | ₩11.42T↑ | ₩11.20T | ₩11.20T↓ | ₩12.25T |
| Gross Profit | ₩2.48T↑ | ₩1.90T↓ | ₩2.39T↑ | ₩1.50T↓ | ₩2.32T |
| Operating Income | ₩437.67B↓ | ₩476.78B↓ | ₩679.72B↑ | -₩413.26B↓ | -₩49.69B |
| Net Income | -₩107.57B↑ | -₩434.34B↓ | ₩119.39B↑ | -₩1.40T↓ | -₩348.22B |
LG Chem, Ltd., together with its subsidiaries, operates as a chemical company in Korea, China, Asia/Oceania, the United States, Europe, and internationally. It offers ethylene-based synthetic resin products, such as ethylene vinyl acetate, high densi...
Moby summary of Pacira BioSciences, Inc.'s Q1 2026 earnings call
Middle East supply disruptions tighten petrochemical feedstocks, pushing costs higher and forcing production cuts across South Korea's chemical sector.
Moby summary of Pacira BioSciences, Inc.'s Q4 2025 earnings call
Pacira BioSciences (NASDAQ:PCRX) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight what CEO Frank Lee described as a “transformative year,” pointing to renewed EXPAREL volume momentum, strengthened intellectual property protection, expanded reimbursement cove
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.